Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 9, 2026

Study Completion Date

November 9, 2027

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

LEAF-4L6715

LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).

DRUG

Supportive Care

Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure

Trial Locations (1)

Unknown

Sorbonne University, Paris

All Listed Sponsors
collaborator

European Cardiovascular Research Center

NETWORK

lead

LEAF4Life, Inc.

INDUSTRY

NCT06640777 - Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter